Refractory anemia with severe dysplasia: clinical significance of morphological features in refractory anemia

Abstract

Refractory anemia (RA) in myelodysplastic syndromes (MDS) are very heterogeneous diseases regarding their morphology, clinical features and survival. We proposed the new designations ‘RA with severe dysplasia (RASD)’ and ‘RA with minimal dysplasia (RAminiD)’. In our criteria, RASD is considered present if a bone marrow (BM) examination shows Pseudo-Pelger–Huet anomalies of mature neutrophils ⩾3% and/or micromegakaryocytes (mMgk) of megakaryocytes ⩾10% in RA patients. RAminiD is defined as RA cases other than RASD. After the reclassification of 58 primary RA patients, the group was composed of 45 RAminiD and 13 RASD patients. The blast percentage in the BM and the frequency of cytogenetic abnormalities observed in the RASD patients were intermediate between those in the RAminiD and RAEB patients. The analysis of survival curves revealed differences among the three groups; the RASD patients had lower survival probabilities than those of the RAminiD group, and significantly higher probabilities than those of the RAEB group. (RAminiD vs RASD, P = 0.06; RASD vs RAEB, P = 0.004.) Our data indicate that in RA patients, RASD is a distinct subset of RA with an unfavorable clinical outcome.